Ozempic continues to storm through the American market as obesity runs rampant. As semaglutide do address some triggers of obesity it does not fix the underlying causes and does not come without concerning side effects. In addition to this - the burden of the US government subsidized health care industry (via Medicare, Medicaid, and private insurance subsidies) in funding this could exceed $1T in a matter of years.
This proposal bans the federal government from paying the cost of semaglutides. This proposal also caps the cost of any semaglutides from a foreign entity ( such as Ozempic) to $200/mo. This enables middle class Americans who choose to opt in on their own dime the ability to afford.
If medicine and healthcare are to help people and extend life, we can remove the exorbitant profit and replace it with a still healthy profit for foreign pharmaceutical companies. This also inhibits foreign entities from financially exploiting systematic issues within the American culture.